topstockalerts
Oct 15, 12:20 AM
Iambic Therapeutics, a San Diego-based clinical-stage life sciences company, priced its initial public offering (IPO) at
$16 per share, selling 9,375,000 common shares and targeting
$150 million in gross proceeds before underwriting discounts, commissions, and other offering expenses. The IPO provides the company with additional capital to support its development as it advances its clinical-stage drug discovery and life sciences programs.
Trading on the Nasdaq Global Select Market is expected to begin on October 15, 2026, under the company's ticker symbol, while the offering is scheduled to close on October 16, subject to customary closing conditions. J.P. Morgan, Jefferies, BofA Securities, and Citigroup are acting as joint book-running managers, overseeing the IPO and coordinating the share distribution to investors.
$JPM $BAC
0 replies